Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Ipsen
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:country |
gptkb:Canada
|
| gptkbp:focusesOn |
rare diseases
|
| gptkbp:foundedIn |
2011
|
| gptkbp:founder |
Dr. Donna Grogan
|
| gptkbp:headquartersLocation |
Montreal, Quebec, Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Clementia Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableContributor |
gptkb:fibrodysplasia_ossificans_progressiva
|
| gptkbp:notableProduct |
palovarotene
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CMTA
|
| gptkbp:bfsParent |
gptkb:Ipsen
|
| gptkbp:bfsLayer |
7
|